Active, not recruitingPhase 4NCT03201848
The Efficacy and Safety of Huaiqihuang Granule in Children With Chronic Primary Immune Thrombocytopenia
Studying Autoimmune thrombocytopenia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Qidong Gaitianli Medicines Co., Ltd
- Principal Investigator
- Runming Jin, ProfessorUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology
- Intervention
- Placebo(drug)
- Enrollment
- 216 enrolled
- Eligibility
- 1-14 years · All sexes
- Timeline
- 2017 – 2024
Study locations (14)
- Guangzhou Women and Children's Medical Center, Guangzhou, Guangdong, China
- The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China
- The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
- Union Hospital of Tongji Medical College, Huazhong University of Science & Technology, Wuhan, Hubei, China
- Wuhan Children's Hospital, Wuhan, Hubei, China
- Children's Hospital of Nanjing Medical University, Nanjing, Jiangsu, China
- Children's Hospital of Soochow University, Suzhou, Jiangsu, China
- Jiangxi Provincial Children's Hospital, Nanchang, Jiangxi, China
- The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China
- The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, China
- First Affiliated Hospital of Xinjiang Medical University, Ürümqi, Xinjiang, China
- Beijing Children's Hospital. Capital Medical University, Beijing, China
- Children's Hospital Capital Institute of Pediatrics, Beijing, China
- Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China
Collaborators
Huazhong University of Science and Technology
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03201848 on ClinicalTrials.govOther trials for Autoimmune thrombocytopenia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07559331High-Dose Dexamethasone Combined With Orelabrutinib Versus High-Dose Dexamethasone Combined With Placebo in Adult Patients With Newly Diagnosed Primary Immune ThrombocytopeniaShandong University
- RECRUITINGPHASE2NCT07362199Anti-CD38 Monoclonal Antibody Combined With Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)Institute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE2NCT07362238Daratumumab Versus Rituximab in the Management of Pediatric Primary Immune Thrombocytopenia (ITP)Institute of Hematology & Blood Diseases Hospital, China
- RECRUITINGEARLY PHASE1NCT07441525UCAR-T Targeting CD19/BCMA in Subjects With Autoantibody-Mediated Autoimmune Benign Hematological DiseasesUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology
- RECRUITINGPHASE2NCT07234019Rituximab Combining Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)Institute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE2NCT07297563Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)Institute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE2NCT07294365A Study of DZD8586 in Adults With Primary Immune Thrombocytopenia (ITP) (TAI-SHAN11)Dizal Pharmaceuticals
- RECRUITINGPHASE2NCT07104565Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell DisordersIncyte Corporation